Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Emerging treatment strategies for extrapulmonary neuroendocrine carcinomas

Nikolaos Trikalinos • 5 Jun 2023
ASCO 2023
Neuroendocrine Tumor FOLFOX Liposomal irinotecan

Nikolaos Trikalinos, MD, MS, Washington University, St. Louis, MO, discusses novel therapeutic regimens under investigation for the treatment of extrapulmonary neuroendocrine carcinomas. Whilst platinum-based therapies were previously utilized, research is underway to asses nanoliposomal irinotecan (nal-IRI) or FOLFOX-based treatments in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nikolaos Trikalinos

Evaluating cabozantinib monotherapy in high-grade neuroendocrine neoplasms
1:25
Evaluating cabozantinib monotherapy in high-grade neuroendocrine neoplasms
Nikolaos Trikalinos • 31 May 2026
CABINET: efficacy of cabozantinib in NETs hormone functional status
1:39
CABINET: efficacy of cabozantinib in NETs hormone functional status
Nikolaos Trikalinos • 31 May 2026
Cabozantinib expands treatment options in neuroendocrine tumors
0:57
Cabozantinib expands treatment options in neuroendocrine tumors
Nikolaos Trikalinos • 31 May 2026
Highlights at ASCO 2023
0:39
Highlights at ASCO 2023
Nikolaos Trikalinos • 5 Jun 2023

Related Videos

Prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors
1:40
Prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors
Rocio Garcia-Carbonero • 2 Jul 2026
DLL3: a promising target in neuroendocrine carcinomas
2:44
DLL3: a promising target in neuroendocrine carcinomas
Rocio Garcia-Carbonero • 2 Jul 2026
Current and emerging strategies for targeting NETs
7:13
Current and emerging strategies for targeting NETs
Rocio Garcia-Carbonero • 2 Jul 2026
Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC
1:43
Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC
Zhonglin Hao • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals